HSPB1
MOLECULAR TARGETheat shock protein family B (small) member 1
HSPB1 (heat shock protein family B (small) member 1) is targeted by 36 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting HSPB1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Disulfiram | 1.39 | 3 |
| 2 | Hexachlorophene | 1.39 | 3 |
| 3 | Zearalenone (S-(E))-3,4,5,6,8,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradec in-1,7(8H)-dione. | 1.39 | 3 |
| 4 | Vitamin | 1.10 | 2 |
| 5 | Bufotenin | 1.10 | 2 |
| 6 | Clotrimazole | 1.10 | 2 |
| 7 | Feprazone | 1.10 | 2 |
| 8 | Nocodazole Nocodazole is | 1.10 | 2 |
| 9 | Phenoxybenzamine | 1.10 | 2 |
| 10 | Quercetin | 0.69 | 1 |
| 11 | 17 alpha-Hydroxyprogesterone Caproate Hydroxyprogesterone derivative that acts as | 0.69 | 1 |
| 12 | Adapalene | 0.69 | 1 |
| 13 | alpha-Linolenic Acid | 0.69 | 1 |
| 14 | Bortezomib | 0.69 | 1 |
| 15 | Ciclopirox | 0.69 | 1 |
| 16 | Danazol | 0.69 | 1 |
| 17 | eliprodil | 0.69 | 1 |
| 18 | Ethinyl Estradiol | 0.69 | 1 |
| 19 | Ethoxyquin Antioxidant; also | 0.69 | 1 |
| 20 | Idazoxan | 0.69 | 1 |
| 21 | Leflunomide | 0.69 | 1 |
| 22 | Linoleic Acid | 0.69 | 1 |
| 23 | Lithocholic Acid | 0.69 | 1 |
| 24 | Methimazole | 0.69 | 1 |
| 25 | Methylcholanthrene | 0.69 | 1 |
| 26 | Methylnitrosourea | 0.69 | 1 |
| 27 | Mometasone Furoate | 0.69 | 1 |
| 28 | Nisoldipine | 0.69 | 1 |
| 29 | Masoprocol | 0.69 | 1 |
| 30 | Oxymetholone | 0.69 | 1 |
| 31 | rafoxanide | 0.69 | 1 |
| 32 | Sulfathiazole | 0.69 | 1 |
| 33 | Toxaphene | 0.69 | 1 |
| 34 | Triamcinolone Acetonide | 0.69 | 1 |
| 35 | Troglitazone | 0.69 | 1 |
| 36 | vinblastine sulfate | 0.69 | 1 |
About HSPB1 as a Drug Target
HSPB1 (heat shock protein family B (small) member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 36 compounds with documented HSPB1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
HSPB1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.